Status:
COMPLETED
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
Lead Sponsor:
Allist Pharmaceuticals, Inc.
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combin...
Eligibility Criteria
Inclusion
- Male or female ；Healthy subjects aged 18 to 50 years (including both ends) at the time of signing informed consent
- Male subjects weighed ≥50kg, female subjects weighed ≥45kg, body mass index (BMI) was between 19.0 and 26.0kg/m2, BMI= weight (kg)/height 2 (m2), including boundary values.
- Subjects voluntarily signed written informed consent and were able to communicate well with the investigator
Exclusion
- History of severe systemic diseases, history of liver and kidney insufficiency, history of mental illness, history of drug dependence;
- Patients with a history of interstitial pneumonia, pulmonary fibrosis or other interstitial lung diseases who were not eligible for admission by the investigators;
- Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, and have digestive diseases (such as peptic ulcer, pancreatitis, colitis, etc.) within 3 months before the first dose;
- The investigator believes that the subject has any other circumstances that make him or her unfit to participate in this clinical trial
Key Trial Info
Start Date :
November 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2024
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06162169
Start Date
November 25 2023
End Date
February 20 2024
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China, 102206